Three of the five RCTs reported in this systematic review were conducted in Japan. Four out of five RCTs involved healthy individuals, with all trials reporting benefits and minimal side effects. The effects of HE supplements were assessed for a wide range of conditions, including dementia, menopause, depression, anxiety, and mild cognitive impairment (17).

Evidence from one of the RCTs suggested improved cognitive function assessed through MMSE scores (30 in pre-treatment versus 29.19 in post-treatment) and improved Benton visual retention scores (7.13 in pre-treatment versus 6.88 in post-treatment). However, no differences in S-PA scores were observed between the control and intervention groups (1). A greater increase in MMSE scores was observed in a PCT assessing the effects of HE supplements on patients with early Alzheimer’s disease (23.2 in pre-treatment vs. 21.75 post-treatment). This improvement may be attributed to the increased dosage of HE supplements (17). Although HE is more commonly used to alleviate symptoms of cognitive impairment, it is also being considered for conditions such as menopause, irritation, and depression. One study reported a significant decrease in CES-D scores (MD: 3.6 and 2.5 in the intervention and placebo groups, respectively), as well as in KMI and ICI scores in HE groups compared to control (MD: 5.3 and 6 in the intervention and placebo groups, respectively). No difference was observed between the two groups for PSQI scores (5).

Although uncommonly documented, one RCT found that HE supplementation enhanced mood disorders characterized by depression and anxiety in obese patients, along with improving nocturnal rest quality. It elevated circulating pro-BDNF levels without notable changes in BDNF levels. In the long term, participants reported feeling less depressed and anxious following HE supplementation. The study also found that HE helped enhance working memory, complex attention, and reaction time immediately after ingestion. Additionally, the antioxidant effects of HE may provide additional health benefits for cognition with chronic use. No significant improvements in VAS mood (MD: 0.3), VAS mental clarity (MD: 0.2), or SHS general happiness (MD: 0.1) were recorded (18).

Though not often observed, some side effects of HE supplementation include headaches (18), stomach discomfort, diarrhea (17), and epimenorrhea (5).

A year-long study in Taiwan provided robust evidence for the effects of HE supplementation in patients with mild AD. The placebo group exhibited a significant decline in the Cognitive Abilities Screening Instrument score (MD: 3.6), while the HE group demonstrated a significant improvement in the MMSE score (MD: 1.45). Furthermore, a notable difference in IADL scores was observed between the two groups (MD: 0.71 in the intervention group and 0.35 in the placebo group) (19).

Another pilot study reported that HE supplementation may improve performance speed and have potential stress-reducing effects; the investigation revealed that a single HE dosage resulted in quicker performance on the Stroop test 60 min after delivery. Furthermore, a decrease in subjective stress was seen after 28 days of supplementation (20).

Supplements increase the diversity of gut microbiota and short-chain fatty acids (SCFAs). They also lead to lower levels of alkaline phosphatase (ALP), uric acid (UA), creatinine (CREA), and low-density lipoprotein (LDL), along with the downregulation of pathobionts such as Streptococcus thermophilus and Bacteroides caccae (21).

One cohort study investigating the impact of HE supplementation on markers of metabolic flexibility or cognition was included in this systematic review. A total of 24 healthy adults participated in a placebo-controlled, single-blind, parallel longitudinal study to examine the effects of ingesting 10 g of HE daily for 4 weeks. The participants completed a fatiguing graded exercise test on a cycle ergometer to analyze substrate oxidation rates and markers of cardiorespiratory fitness. Subsequently, two dual-task challenges—the Stroop Color Word Test combined with a mental arithmetic task and the Y-Balance Test—were conducted to evaluate markers of cognition in the pre- and post-fatigue states. The study concluded that no significant effects were observed for any dependent variables. Therefore, the study concluded that the ingestion of HE did not affect metabolic flexibility or cognition (22).

Our data screening identified one case report—interestingly, one of the rare cases wherein a side effect of potentially fatal severity was reported. It describes the case of a 63-year-old Japanese man with mild, untreated diabetes mellitus (DM) who had regularly been taking HE supplements from December 2001 until his emergency hospital admission for acute respiratory distress syndrome (ARDS). He presented with low-grade fever, hemosputum, cough, and exertional dyspnea; clinical findings revealed diffuse infiltration in both lungs (23).

A causal relationship between HE supplementation and ARDS was discussed, based on HE’s role in promoting NGF synthesis and producing immunomodulatory effects. A lymphocyte reaction test with the extract yielded significantly positive results, potentially strengthening the evidence. The report concluded that HE contains a compound capable of triggering an allergic reaction (23).

Laboratory studies were primarily conducted in East Asian countries, including China (N = 5), Japan (N = 3), Korea (N = 1), and Taiwan (N = 1). The majority (N = 8) focused on HE effects on cancer cells, with all studies reporting benefits. Cancer-related studies mainly targeted leukemia and gastric cancer. Erinacine A significantly reduced cell proliferation and induced apoptosis in HL-60 cells (8). Other studies reported similar findings of decreased inflammatory responses in human monocytes caused by lipopolysaccharides (24), and extracts of HE induced NO production in macrophage cells, suppressing the proliferation of U937 and inducing apoptosis (25).

HE’s effect on gastric cancer cells shows that HEG-5 significantly affects apoptosis, cell proliferation, and the cell cycle of SGC-7901 by promoting cell cycle arrest at the S phase (26). However, there are also reports of HE extracts inducing in vitro cytotoxicity against gastrointestinal cancers (7).

One computer analysis study was identified during our screening. A combination of machine learning and structural modeling was used to identify compounds from HE with AChE-inhibiting activities (27).

A deep learning neural network was developed to rapidly screen compounds for their potential to inhibit AChE activity. Deep learning models were also applied to screen compounds in the BACMUSHBASE database (28). Five promising compounds from HE were identified, among which erinacine A and hericenone B were selected based on further analysis (27).

Subsequently, molecular dynamics simulations and MM/PBSA free energy calculations for erinacine A and hericenone B were compared with those of approved drug molecules. Further analysis revealed that these compounds exhibited binding energy profiles similar to those of donepezil and galantamine. Similarities were also observed in their binding mechanisms, suggesting that erinacine A and hericenone B may have the potential to serve as alternative AChE-targeting drugs. The study concluded that both compounds are suitable candidates for further research and development as AD medications (27).

In our review, multiple studies showed that HE provides beneficial effects on cognitive function and neurotrophic regulation (1, 17). These cognitive benefits are attributed to its capacity to stimulate NGF synthesis and support neuroplasticity (20). Neurotrophins are essential for the survival, adaptation, and differentiation of neurons and are primarily associated with the central nervous system. Survival signals are mediated through the activation of the high-affinity receptor tropomyosin receptor kinase A (TrkA), while cell death is induced via p75NTR binding. Erinacines A, B, and C are diterpenoids isolated from HE-cultured mycelia, and spectral and enzymatic analysis have shown that they exhibit strong NGF-stimulating activity (2).

One study in our review reported that HE supplementation increased circulating pro-BDNF concentrations without a corresponding change in mature BDNF levels (28). BDNF plays a central role in learning, memory consolidation, and synaptic plasticity (29). Homozygous mutation of the BDNF gene has been associated with degeneration in sensory and vestibular pathways, leading to coordination deficits (31). Overexpression of TrkB enhances memory, while underexpression leads to impaired spatial memory. BDNF is also associated with aging, and some recent findings suggest that age-related physiological and pathological changes in the CNS can be altered by either stimulating receptor expression or by varying BDNF administration. Additionally, BDNF supports the survival and function of several neuronal populations, including mesencephalic dopaminergic, septal cholinergic, and striatal GABAergic neurons (30).

Neuronal function and survival depend on balanced levels of reactive oxygen species (ROS) and reactive nitrogen species (RNS) to maintain synaptic plasticity. Excessive ROS/RNS levels are known to play a detrimental role in the pathogenesis of neurodegenerative disorders. Substantial evidence indicates that neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s disease (HD) are characterized by increased levels of oxidation markers and decreased antioxidant ability, leading to excitotoxicity, mitochondrial dysfunction, and apoptosis. The role of BDNF is particularly significant in inhibiting neuronal death caused by oxidative stress–mediated degeneration, ischemia, and amyloid-β toxicity (31, 32).

Across the studies included in our review, administration of HE was generally associated with beneficial signals on cognitive outcomes and neurotrophic markers, although the evidence base remains heterogeneous and limited in size. One such study (1) reported increased MMSE scores when comparing pre- and post-intervention assessments, indicating improved global cognition (MD: 0.81). Consistent directional effects were observed across randomized controlled trials and experimental models, including an earlier study by Mori et al. (17), which also found that HE is effective in improving mild cognitive impairment.

In a similar study evaluating both acute and 28-day chronic HE administration (1.8 g/day), a single dose produced a statistically significant improvement in Stroop task speed (p = 0.005). With continued daily intake over 28 days, investigators observed a trend toward reduced stress (p = 0.051) but did not detect significant gains in cognition or memory, underscoring the need for longer-duration trials (20).

Apoptosis can occur through either an extrinsic or death receptor-mediated pathway, or an intrinsic, mitochondrial-mediated pathway. The triggering event of the extrinsic pathway is when death ligands such as Fas ligand, tumor necrosis factor-related apoptosis-inducing ligand, or tumor necrosis factor receptor 1 bind to their cell surface death receptors, triggering the formation of the death-inducing signaling complex, leading to the activation of caspase-8. This activates downstream effector caspases such as caspase-3 to execute apoptosis. Additionally, the intrinsic pathway is activated by intracellular stress signals, such as ROS or DNA damage. These stress signals cause mitochondrial outer membrane permeabilization, leading to the release of cytochrome c into the cytosol (37). Cytochrome c then binds with Apaf-1 and procaspase-9 to form a complex called the apoptosome. This results in the activation of caspase-9, which subsequently activates caspase-3 to carry out apoptosis. The role of pro-apoptotic proteins Bax and Bad, and anti-apoptotic proteins such as Bcl-2 and Bcl-XL, is to regulate this pathway by balancing mitochondrial membrane permeability, either by allowing or preventing the release of cytochrome c (38).

The phosphoinositide 3-kinase/protein kinase B signaling pathway (PI3K/AKT) is a key component of numerous biological processes, including cell growth and proliferation, survival and apoptosis, metabolic regulation, angiogenesis, as well as adipogenesis and adipocyte differentiation. When activated, the pathway promotes the activity of anti-apoptotic proteins such as B-cell lymphoma 2 and B-cell lymphoma extra-large, while suppressing pro-apoptotic molecules. This stabilizes the mitochondrial membrane and prevents cell death. In cancer, the continuous activation of the PI3K/AKT pathway supports uncontrolled proliferation and resistance to treatment by blocking key steps in cellular apoptosis (39, 40).

Experimental data now clearly demonstrate that HE compounds, such as erinacine A, induce apoptosis through the intrinsic mitochondrial pathway. These mechanisms include the upregulation of pro-apoptotic proteins such as Bax, the downregulation of anti-apoptotic proteins such as Bcl-2 and Bcl-xL, and the release of cytochrome c, alongside increased TRAIL expression and ROS generation. The loss of mitochondrial membrane potential and the activation of cleaved caspase 9 and caspase 3 are all key characteristics of mitochondrial apoptosis. A proteomic analysis of human gastric cancer cells treated with erinacine A revealed notable shifts in protein expression, marked by the upregulation of tumor suppressors 14-3-3σ (1433S) and MTUS2, and a reduction in nucleophosmin (NPM). In addition to these findings, increased ROS production and the activation of the FAK/AKT/p70S6K and PAK1 signaling pathways suggest a mechanism that drives apoptosis and reduces the invasiveness of gastric cancer cells (36).

A study assessing the induction of apoptosis by erinacine A in human colorectal cancer cells demonstrated that erinacine A elevates the expression of the principal death receptor components of the extrinsic apoptotic pathway: tumor necrosis factor receptor-1 (TNFR1), Fas (CD95), and Fas ligand (FasL). Their coordinated upregulation promotes the assembly of death-inducing signaling complexes at the plasma membrane, thereby activating the initiator caspase-8 via proteolytic cleavage.

Activated caspase-8 then propagates the downstream caspase cascade that executes apoptosis. In parallel, erinacine A enhances intracellular signaling through c-Jun N-terminal kinase (JNK), the transcriptional co-activator and histone acetyltransferase p300, and the NFκB (p50) axis. JNK phosphorylation modulates transcription factor activity; p300 mediates chromatin relaxation through histone acetylation to increase promoter accessibility; and NFκB p50 contributes to the transcriptional activation of apoptosis-related target genes (41).

Several studies included in this review corroborate these findings, showing that treatment with erinacine A results in the activation of TRAIL, caspase 8, caspase 9, and caspase 3, as well as the release of cytochrome c, whereas there is a decrease in the cellular levels of Bcl-2 and Bcl-XL in erinacine A-induced apoptosis (36).

Another study in this review found that hericerin A effectively inhibited the growth of HL 60 human acute promyelocytic leukemia cells. This growth inhibition was predominantly caused by the activation of apoptosis, as demonstrated by cellular alterations such as chromatin condensation, the development of apoptotic bodies, and an increase in sub-G1 cell numbers. In addition, these compounds were shown to upregulate the pro-apoptotic protein Bax while downregulating the anti-apoptotic protein Bcl-2, resulting in caspase-3 activation and subsequent poly (ADP-ribose) polymerase cleavage, as observed in previous studies.

Furthermore, its pro-apoptotic activity was connected to the inhibition of the PI3K/AKT signaling pathway, with lower levels of phosphorylated AKT and the oncogenic transcription factor c-myc. Notably, these compounds showed minimal cytotoxicity against normal HEL-299 fibroblasts, indicating their potential as selective anticancer agents (8). HEG-5, a compound found within Hericium erinaceus, significantly inhibited the proliferation and colony formation of 19 SGC-7901 cells by inducing apoptosis and causing cell cycle arrest at the S phase. RT-PCR and Western blot analysis suggested that HEG-5 could decrease the expression of Bcl2, PI3K, and AKT1 (21) while increasing the expression of Caspase-8, Caspase-3, p53, CDK4, Bax, and Bad. These findings indicate that Caspase-8/−3-dependent, p53-dependent mitochondrial-mediated pathways (23), along with the PI3k/Akt signaling pathways, are involved in the molecular events leading to HEG-5–induced apoptosis and cell cycle arrest (26).

Despite the promising anticancer effects of HE’s bioactive compounds demonstrated in vitro, several limitations must be acknowledged. The majority of studies have been conducted using cancer cell lines under controlled laboratory conditions, and they do not account for the complexity of tumor biology, such as in vivo models, including tumor microenvironment interactions, immune responses, and pharmacokinetics. Furthermore, there is a lack of in vivo studies and clinical trials investigating the efficacy, bioavailability, metabolism, and potential toxicity of HE compounds such as erinacine A, hericerin, and HEG-5. Given the increased variability in experimental designs, there is a lack of generalizability of findings across studies. Additionally, although several signaling pathways have been implicated in HE-induced apoptosis, the precise molecular targets and their effects are not fully characterized. Moreover, while the selective cytotoxicity of HE compounds toward cancer cells over normal cells is encouraging, it requires further validation in physiologically relevant models to confirm therapeutic windows and minimize adverse effects.

HE is rich in a variety of active ingredients such as polysaccharides, diterpenes, pyranones, phenols, and sterols (42). Recently, polysaccharides have become the primary derivatives of HE and have become the subject of research. HEPs exert their effects on SCFA production through several mechanisms, primarily attributed to their high content of indigestible polysaccharides, especially β-glucans and heteropolysaccharides. These bioactive polysaccharides largely resist digestion in the upper gastrointestinal tract, reaching the colon intact and acting as fermentable substrates for beneficial gut microbiota (43, 44). Notably, HE polysaccharides stimulate SCFA-producing bacteria, enhancing the synthesis of SCFAs, particularly butyrate, acetate, and propionate (21, 43). Evidence from both animal models and in vitro studies demonstrates that fermentation of HEPs prompts an increase in the abundance of these beneficial genera, resulting in elevated levels of total and specific SCFAs in the gut.

SCFAs are carboxylic acids with fewer than six carbon atoms, primarily comprising acetate (C2), propionate (C3), and butyrate (C4). These key metabolites are produced by gut microbiota through the anaerobic fermentation of indigestible carbohydrates, including dietary fibers and polysaccharides, in the colon (45, 46). SCFAs exert systemic and local physiological effects via multiple mechanisms, including serving as a key energy source for colonocytes, supporting the intestinal barrier’s integrity by promoting tight junction proteins (e.g., claudin-1, zonula occludens-1) and mucins (e.g., Mucin 2), and modulating immune responses via both direct and receptor-mediated pathways (45). SCFAs function as important signaling molecules, particularly through the activation of G-protein-coupled receptors such as FFAR2 (GPR43), FFAR3 (GPR41), and HCA2 (GPR109A), which are expressed on diverse cell types, including immune cells, colonocytes, and neurons. Additionally, SCFAs, especially butyrate, influence gene expression by inhibiting histone deacetylases, thereby affecting anti-inflammatory processes and cellular differentiation (45, 47).

Furthermore, SCFAs support metabolic regulation by influencing gluconeogenesis and lipid metabolism, increasing the production of glucagon-like peptide 1, suppressing inflammatory processes, protecting against insulin resistance, and exhibiting anti-tumor activity. Deficiencies or imbalances in SCFA production have been associated with disorders such as inflammatory bowel disease, metabolic syndrome, and certain neuropsychiatric conditions, highlighting their essential role in maintaining gut and overall health (45, 46).

Recent literature suggests that HE supplementation may influence the alpha diversity of gut microbiota and upregulate SCFA-producing bacteria in humans. The primary clinical evidence in this regard is derived from a single PCT conducted in China, which concluded that daily HE supplementation over seven days in healthy adults led to a significant increase in SCFA-producing genera, including Kineothrix alysoides, Gemmiger formicilis, Fusicatenibacter saccharivorans, Eubacterium rectale, and Faecalibacterium prausnitzii. Concurrently, potential opportunistic bacteria such as Streptococcus thermophilus, Bacteroides caccae, and Romboutsia timonensis were downregulated. The shift in microbiota diversity was associated with a favorable reduction in levels of alkaline phosphatase, low-density lipoprotein, uric acid, and creatinine after HE intervention (21).

Although promising, it should be noted that this was the only published human clinical study meeting our inclusion criteria during our comprehensive and systematic search that specifically examined the influence of HE supplementation on SCFA-producing gut bacteria. While this highlights a gap in current clinical literature, the existence of a single robust clinical study with clear and measurable outcomes provides valuable and direct evidence supporting this association.

These results are also corroborated by a number of in vitro and animal studies, which consistently support the findings regarding the effects of HE on gut microbiota and SCFA production. An in vitro study investigated 24 h of fermentation and found that HEPs stimulated total SCFA production (including acetate, propionate, and butyrate) and increased the abundance of SCFA-producing bacteria, namely Bifidobacterium, Faecalibacterium, Blautia, Butyricicoccus, and Lactobacillus. Furthermore, a notable decrease in the relative abundance of opportunistic pathogens, such as Escherichia-Shigella, Klebsiella, and Enterobacter, was observed (43). These studies indicate that the fermentation of HE β-glucans not only increases overall SCFA production but also promotes the proliferation of SCFAs-producing bacterial genera through microbial cross-feeding interactions (44). Therefore, HE β-glucans function as prebiotics, shaping both the composition and metabolic activity of the gut microbiota to favor enhanced SCFA synthesis. Animal studies further support these findings. In rats, supplementation with HEPs led to notable enrichment of beneficial gut bacteria and elevated levels of SCFAs, alongside improvements in intestinal barrier integrity and reductions in inflammation. Similarly, aged dogs fed an HE-enriched diet for sixteen weeks exhibited remarkable shifts in gut microbiota composition, with an increased prevalence of SCFA-producing Bacteroidetes (48). In mice, HEPs supplementation promoted the growth of SCFA-producing bacteria, namely Clostridia UCG-014, Lachnospiraceae_NK4A136, and Eubacterium xylanophilum, while decreasing the abundance of potentially harmful microbes, collectively supporting both gut and systemic health (49). Multiple studies have investigated the modulation of gut physiology by the central nervous system, also known as the gut-brain axis. This bidirectional system integrates neural, immune, endocrine, and metabolic signaling pathways to regulate numerous functions, such as motility, secretion, and nociception. HEPs foster the proliferation of beneficial gut microbiota, such as Faecalibacterium, Bifidobacterium, and Blautia, which modulate the synthesis of neuroactive compounds, neurotransmitters, and immune mediators, including serotonin and gamma-aminobutyric acid (GABA), that communicate directly with the central nervous system (21, 46).

HE contains neuroactive compounds, namely erinacines and hericenones, which promote the synthesis of neurotrophins such as NGF and BDNF, both essential for neural growth, synaptic plasticity, and overall neuronal health (50). By increasing the abundance of favorable microbiota, HE increases the production of microbial metabolites such as SCFAs, which contribute to an anti-inflammatory effect supporting both gut and brain health (46). SCFAs reach the brain either by crossing the blood–brain barrier or through neural signaling pathways such as the vagus nerve, influencing neuroinflammation and neural circuits involved in mood, cognition, and neuroprotection (51). This allows SCFAs to interact with microglia, astrocytes, and neurons, mediating their effects through G-protein-coupled receptors (FFAR2/FFAR3), epigenetic modifications (including inhibition of histone deacetylases), and modulation of BDNF in brain regions involved in emotion and cognition. Furthermore, the shifts in microbiome composition induced by HE have demonstrated reduced gut permeability, thereby limiting the translocation of bacterial components such as lipopolysaccharides into the bloodstream and subsequently diminishing both systemic and neuroinflammation. Elevated lipopolysaccharide levels influence neuroinflammatory cascades, which are strongly associated with depression, anxiety, and neurodegenerative disorders (46, 51). Beyond these immunomodulatory effects, preclinical trials indicate that HE and its metabolites can activate signaling pathways such as ERK/CREB in hippocampal neurons, increasing neurotrophic factor expression and supporting neurogenesis (50). Collectively, these findings suggest that HE can exert a multifaceted influence on the gut-brain axis, enhancing microbiota composition, reducing inflammation, and directly modulating neurotrophic and neurotransmitter systems.

HE’s bioactive compounds, particularly hericenones and erinacines, can cross the blood–brain barrier and enhance the production of neurotrophic factors such as NGF, BDNF, and pro-BDNF. NGF and BDNF are vital for synaptic plasticity, neurogenesis, and overall neuronal survival, whereas pro-BDNF activates apoptotic pathways in neurons and glial cells. An imbalance or defect in these neurotrophins could result in cognitive impairment, psychiatric disorders, and anxious behavior (52). A key mechanism involves the hypothalamic–pituitary–adrenal (HPA) axis, a critical neuroendocrine system that modulates stress responses. Animal studies suggest that supplementation with HE can normalize the activity of the HPA axis by attenuating stress-induced elevations in corticosterone, thereby reducing both physiological and behavioral indicators of chronic stress. Furthermore, evidence suggests that HE supplementation modulates the gut-brain axis by promoting the growth of beneficial gut bacteria that produce anti-inflammatory and neuroactive metabolites, such as SCFAs, which influence brain function. Emerging research further implicates HE in the regulation of neurotransmitter synthesis and signaling, including serotonin and GABA, which are integral to emotional stability and mood regulation.

Several clinical and preclinical studies have demonstrated that HE supplementation leads to reductions in symptoms associated with depression, anxiety, binge eating, and sleep disorders, as demonstrated by significant changes in standardized scales such as CES-D and KMI (5, 52). For example, an 8-week supplementation trial involving overweight and obese adults revealed significant decreases in depression and anxiety scores, measured by Zung’s depression and anxiety scales. Increases in pro-BDNF/BDNF ratios were also observed within this study, suggesting a link between neurotrophic support and psychological outcomes.

Additionally, a double-blind, placebo-controlled trial investigated the potential of daily HE consumption in individuals diagnosed with AD. The study utilized a comprehensive list of neuropsychological assessments, including the Neuropsychiatric Inventory (NPI) for behavioral symptoms, the Cognitive Abilities Screening Instrument (CASI) to evaluate multiple cognitive domains, the MMSE for global cognitive function, and the Instrumental Activities of Daily Living (IADL) to understand functional autonomy. The intervention group demonstrated notable improvements in NPI scores, reflecting a reduction in neuropsychiatric symptoms such as agitation, depression, and anxiety. HE consumption also resulted in an increase in CASI scores, indicating enhanced attention, memory, language, and visual construction abilities.

Furthermore, a significant increase in the MMSE scores of the intervention group was noted, suggesting either maintained or improved cognitive status compared to the placebo group, potentially mitigating cognitive decline. Lastly, IADL scores were also greater in the HE group, representing a lower dependence level and participants’ improved ability to perform everyday tasks independently. The findings provide preliminary but encouraging evidence of the potential of HE to exert beneficial effects on both behavioral and cognitive symptoms in individuals with mild AD (19).

Another clinical study examined the impact of HE on psychological well-being and menopausal symptoms in a randomized cohort. Participants were assessed using several validated tools, including the KMI, CES-D, PSQI, and ICI. Participants from the HE groups obtained significantly lower scores on the CES-D, suggesting a decrease in depressive symptoms. Moreover, upon HE consumption, scores on the ICI showed a significant decline, with the most remarkable advances being in symptoms such as “palpitation,” “insensitive,” “irritating,” “anxiety,” and “concentration” (5), indicating that HE can produce a meaningful reduction in symptoms associated with depression and anxiety through the promotion of hippocampal neurogenesis, which has been proven to be correlated with behavioral and emotional improvements. Additionally, HE consumption leads to the modulation of serotonin receptors, which contributes to the anxiolytic and antidepressant effects observed (53).